E. S. Gubanov

E. S. Gubanov

Auto-generated profile, based on publicly available information

E. S. Gubanov

Medical University “Reaviz

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2022 in Andrology and Genital Surgery
Verified
Journal Article
Open access
PDF file
PKP. S. Kyzlasov
P. S. Kyzlasov
EGE. S. Gubanov
E. S. Gubanov
ЕГЕ. А. Гринь
Е. А. Гринь
NNN. A. Nashivochnikova
N. A. Nashivochnikova
SKS. S. Krasnyak
S. S. Krasnyak
Background. Peyronie’s disease is a disease characterized by chronic inflammation of the protein membrane of the fibrous tissue of the penis. Oral pharmacotherapy allows a long-term effect on the mechanisms of formation of fibrous plaque. Aim. To evaluate the degree of change in complaints against the background of the complex drug Peyroflex ® and its effectiveness. Materials and methods. The study was conducted as a prospective observational study. The study included 43 patients with complaints of pain in the penis area during erection or at rest, curvature of the penis, the presence of palpable plaque in the area of the cavernous bodies. Men took Peyroflex ® on a regular basis, one capsule (410 mg) 2 times a day for 6 months or until the pain disappeared during erection, but not less than 6 months. Results. The intensity of pain after 3 and 6 months of taking Peyroflex ® decreased by 47.8 and 78.3 %, respectively. The severity of penile curvature showed a tendency to decrease by 7.5 % after 3 doses of Peyroflex ® and remained stable after 6 months. The plaque area according to the results of ultrasound examination after 3 and 6 months of taking Peyroflex ® decreased by 14.7 and 17.2 %, respectively. Conclusion. Peyroflex ® can be recommended for use in the active phase of Peyronie’s disease both in monotherapy and in combination with other methods of treatment (extracorporeal shock wave therapy, physiotherapy, etc.).

9 May 2026 in Andrology and Genital Surgery
Verified
Journal Article
Open access
PDF file
PKP. S. Kyzlasov
P. S. Kyzlasov
AAA. S. Al-Shukri
A. S. Al-Shukri
EGE. S. Gubanov
E. S. Gubanov
MKM. R. Kolomijceva
M. R. Kolomijceva
BACKGROUND : Despite advances in medicine, conservative treatment of Peyronie’s disease (PD) remains challenging due to an incomplete understanding of its pathogenesis and limited evidence base, often necessitating surgical intervention. AIM : To evaluate the efficacy and safety of the combined use of Peyroflex® capsules and gel on PD symptoms (pain, penile curvature, fibrous plaque size). METHODS : A prospective comparative cohort study was conducted involving 82 patients with acute-phase PD. Participants were randomized into to 4 groups: 1) Peyroflex® capsules and gel; 2) Peyroflex® Gel + shock wave therapy (SWT); 3) Peyroflex® capsules + gel + SWT; 4) SWT (control group). The follow-up period was 6 months. Primary endpoints included changes in penile curvature (degrees), fibrous plaque area (mm2), and pain intensity measured by Visual Analogue Scale (scores). RESULTS : Combination therapy with Peyroflex® line products (Group 1) demonstrated a statistically significant reduction in plaque area (from 88.7 to 69.6 mm2; p <0.001) and a trend towards reduced curvature angle. The best outcomes were achieved in Group 3 (Peyroflex® capsules + gel + SWT): curvature angle decreased from 21.1° to 13.9° (a 34.1 % reduction; p <0.001), and plaque area decreased by 51.5 % (p <0.001). The addition of Peyroflex® Gel to SWT (Group 2) enhanced the efficacy of SWT: curvature reduction was 28.4 % versus 16.3 % in the control group (p = 0.002). Pain was resolved in all groups. No adverse events were reported. CONCLUSION : The use of Peyroflex® line products, especially in combination with SWT, demonstrates high clinical efficacy in the treatment of acute-phase PD, leading to regression of fibrous plaque and curvature. Therapy with Peyroflex® line products alone also represents an effective conservative treatment option.